Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

Annals of Oncology

Volumn 27, Issue 10, 2016, Pages 1895-1902

  Joerger, Markus ^a   von Pawel, J ^b   Kraff, S ^c   Fischer, J R ^d   Eberhardt, W ^e   Gauler, T C ^e   Mueller, L ^f   Reinmuth, N ^g   Reck, M ^g   Kimmich, M ^h   Mayer, F ⁱ   Kopp, H G ^j   Behringer, D M ^k   Ko, Y D ^l   Hilger, R A ^e   Roessler, M ^m,n   Kloft, C ^o   Henrich, A ^o   Moritz, B ^m,n   Miller, M C ^p   Salamone, S J ^p   Jaehde, U ^c   more..

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b Pneumology Clinic   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d Klinik Lowenstein   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f Praxis Leer   (Germany)

^g Member of the German Center for Lung Research   (Germany)

^h Klinik Schillerhohe   (Germany)

ⁱ UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^j UNIVERSITY OF TÜBINGEN   (Germany)

^k Augusta Kranken Anstalt   (Germany)

^l Johanniter Krankenhaus   (Germany)

^m CESAR Central Office   (Austria)

ⁿ CESAR Central European Society for Anticancer Drug Research EWIV   (Austria)

^o FREIE UNIVERSITÄT BERLIN   (Germany)

^p SALADAX BIOMEDICAL INC   (United States)

more..

Author keywords

Neuropathy; Non small cell lung cancer; Paclitaxel; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY SURFACE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION RESPONSE; RANDOMIZED CONTROLLED TRIAL; SEX; TREATMENT RESPONSE; VALIDATION STUDY; ADOLESCENT; ADVERSE DRUG REACTION; CLASSIFICATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; PATHOLOGY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL;

EID: 85007514026     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/ANNONC/MDW290     Document Type: Article

References (20)

1. Belani CP, Ramalingam S, Perry MC et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 2008; 26: 468-473
2. Augusto C, Pietro M, Cinzia M et al. Peripheral neuropathy due to paclitaxel: study of the temporal relationships between the therapeutic schedule and the clinical quantitative score (QST) and comparison with neurophysiological findings. J Neurooncol 2008; 86: 89-99
3. Hensing TA, Peterman AH, Schell MJ et al. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 2003; 98: 779-788
4. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 5892-5899
5. Henningsson A, Karlsson MO, Vigano L et al. Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 2001; 19: 4065-4073
6. Mathijssen RH, de Jong FA, Loos WJ et al. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? Oncologist 2007; 12: 913-923
7. de Graan AJ, Elens L, Sprowl JA et al. CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin Cancer Res 2013; 19: 3316-3324
8. Joerger M, Huitema AD, Richel DJ et al. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. Clin Pharmacokinet 2007; 46: 1051-1068
9. Joerger M, Huitema AD, van den Bongard DH et al. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of paclitaxel in patients with solid tumors. Clin Cancer Res 2006; 12: 2150-2157
10. Joerger M, KraffS, Huitema AD et al. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. Clin Pharmacokinet 2012; 51: 607-617
11. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247
12. Zufia Lopez L, Aldaz Pastor A, Aramendia Beitia JM et al. Determination of docetaxel and paclitaxel in human plasma by high-performance liquid chromatography: validation and application to clinical pharmacokinetic studies. Ther Drug Monit 2006; 28: 199-205
13. Joerger M, Huitema AD, Richel DJ et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancerpharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res 2007; 13: 6410-6418
14. Hershman DL, Lacchetti C, Dworkin RH et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014; 32: 1941-1967
15. Rowinsky EK, Jiroutek M, Bonomi P et al. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin Cancer Res 1999; 5: 767-774
16. Di Maio M, Gridelli C, Gallo C et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 2005; 6: 669-677
17. Gamelin E, Delva R, Jacob J et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2099-2105
18. Evans WE, Relling MV, Rodman JH et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998; 338: 499-505
19. Cline DJ, Zhang H, Lundell GD et al. Development and evaluation of a nanoparticle-based immunoassay for determining paclitaxel concentrations on routine clinical analyzers. Ther Drug Monit 2013; 35: 809-815
20. KraffS, Lindauer A, Joerger M et al. Excel-based tool for pharmacokinetically guided dose adjustment of paclitaxel. Ther Drug Monit 2015; 37: 725-732